Parkinson’s Disease Rat Model

Bioanalytical Services
Phenotyping Services
Oncology PlatformMetabolism PlatformEfficacy and Pathology Platform
Anti-Tumor Drug Efficacy Evaluation
Patient Derived Xenograft (PDX) Mouse Models and Efficacy ServicesHumanized Immune Checkpoint Mouse Models and Efficacy Services
Non-GLP Toxicity Assessment Services
Metabolic Disease Efficacy Evaluation
Obesity Models and Efficacy ServicesType II Diabetes Models and Efficacy ServiceLiver Disease Models and Efficacy ServicesAtherosclerosis Models and Efficacy ServicesHyperlipidemia Models and Efficacy ServicesGout/Hyperuricemia Models and Efficacy Services
Autoimmune Disease Efficacy Evaluation
Neurodegenerative Disease Efficacy Evaluation
Parkinson’s Disease Rat ModelIn Vitro TestingIn Vivo Biochemical ExaminingBehavioral AnalysisIn Vivo Drug Efficacy Evaluation
Cell Therapy & Gene Therapy Efficacy Evaluation

Parkinson's disease (PD) is a progressive neurodegenerative disease that is characterized by a combination of motor and non-motor symptoms. GemPharmatech has successfully developed a PD rat model by precisely stereotaxically injecting 6-OHDA into both the Substantia Nigra pars compacta (SNc) and Ventral Tegmental Area (VTA). This well-constructed PD model offers a powerful tool for in-depth research and drug development, enabling a more comprehensive understanding and potential therapeutic interventions for PD.


6-OHDA induced PD rat model



▎Model Construction Strategy


1.png

Data collection

  • Body weight

  • Survival proportion

  • Behavior test

  • Hematoxylin-eosin staining

  • Nissl body staining

  • Immunofluorescence staining (TH, Iba1, GFAP)

 

▎Body Weight Change and Survival Rate of the PD Model


2.png

(data presented as Mean±SEM，n=6)


The body weight of the PD model was lower than the control group after unilateral stereotaxic injection. In the first week after unilateral stereotaxic injection of 6-OHDA, approximately 15% death was observed.

 

▎Confirmation of Successful Induction of PD by 6-OHDA

 

3.png

(data presented as Mean±SEM，n=6)


Three weeks after unilateral stereotaxic injection of 6-OHDA, subcutaneous injection of apomorphine (0.5 mg/kg) caused the rats to rotate toward the uninjured side. Rats that rotated more than 210 times (7 turns/minute) within 30 minutes were identified as PD models.

 

▎Behavior Test: Rotarod


8.png 


The PD rat model showed deficits in motor learning and motor coordination in the rotarod test.

 

▎Pathology: HE and NISSL body staining of Substantia Nigra


4.png


Unilateral stereotaxic injection of 6-OHDA into both the Substantia Nigra pars compacta (SNc) and Ventral Tegmental Area (VTA)

 

▎Pathology: IBA1+ and GFAP+ staining in Substantia Nigra


5.png


Eight weeks after 6-OHDA injection, IBA1+ (microglial marker) and GFAP+ (astrocyte marker) staining was significantly increased in the injection position of the substantia nigra of the PD model.

 

▎Pathology: TH+ neurons in Substantia Nigra and Striatum


图片3.jpg


Eight weeks after 6-OHDA injection, TH+ neuron loss was observed in the striatum and substantia nigra on the injured side of the PD model.

 

▎Pathology: IBA1+ and GFAP+ staining in Striatum


6.png


Eight weeks after 6-OHDA injection, IBA1+ and GFAP+ staining in the striatum showed no difference among three groups.

 

▎Pathology: IBA1+ and GFAP+ staining in Hippocampus


7.png


Eight weeks after 6-OHDA injection, IBA1+ and GFAP+ staining in the hippocampus showed no difference among three groups.


TALK WITH OUR EXPERTS

GemPharmatech is committed to protecting and respecting your privacy, and we'll only use your personal information to administer your account and to provide the products and services you requested from us. From time to time, we would like to contact you about our products and services, as well as other content that may be of interest to you. If you consent to us contacting you for this purpose, please click below to say how you would like us to contact you:

In order to provide you with the content requested, we need to store and process your personal data. If you consent to us storing your personal data for this purpose, please click the checkbox below.

You can unsubscribe from these communications at any time. For more information on how to unsubscribe, our privacy practices, and how we are committed to protecting and respecting your privacy, please review our Privacy Policy.